Navigation Links
Mylan Files Annual Report on Form 10-K for Year Ended Dec. 31, 2009
Date:3/2/2010

PITTSBURGH, March 2 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its Annual Report on Form 10-K, containing audited consolidated financial statements for the year ended Dec. 31, 2009, as filed with the U.S. Securities and Exchange Commission on Feb. 26, 2010, is available through its Web site (www.mylan.com). In addition, the company's shareholders may receive a hard copy of the Annual Report, free of charge, upon request to Investor Relations at 724-514-1813.

This press release is being issued pursuant to NASDAQ Listing Rule 5250(d)(1)(C).

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.

SOURCE Mylan Inc.

Back to top

RELATED LINKS
http://www.mylan.com

'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets
2. Mylan Parts Ways with Chief Financial Officer Jolene Varney
3. Mylan Launches First Generic Version of Xopenex(R) Inhalation Solution (Concentrate), 0.25%
4. Mylan Begins Marketing First Generic Version of BenzaClin(R) Acne Treatment
5. Mylans Matrix Receives First and Only Tentative FDA Approval Under PEPFAR for Generic Version of Atripla(R) HIV Treatment
6. Mylan Pharmaceuticals Receives Final FDA Report and Reaffirms Its 48-Year Exemplary Record of Quality
7. President Clinton and Mylan Chairman and CEO Robert J. Coury Announce New Agreement to Lower Price of Treatment for Patients with Drug-Resistant HIV in Developing Countries
8. Mylan Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Closing Bell
9. Mylan Announces Enhancements to Executive Management Team
10. Mylan Reports That the FDA Determined That All Accusations Were Unfounded
11. Mylan Reiterates and Stands Behind Its 48-Year Commitment and Track Record of Quality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... Silicon Valley ... even on the go. Their electric toothbrushes aggressively attack oral bacteria by reducing ... sanitizing technology. Combining leading edge Enke technology with a premium timeless design, they ...
(Date:9/22/2017)... ... September 22, 2017 , ... “Letters From Home”: a moving ... lost, have value to God. “Letters From Home” is the creation of published author, ... the President’s Cabinet of Jerry Savelle Ministries International, who has traveled and ministered on ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... and create life. Although frozen embryos have a slight statistical advantage for live ... freezing is a wonderful opportunity for women undergoing medical treatment or who are ...
(Date:9/21/2017)... ... 21, 2017 , ... With ProSlideshow Portrait from Pixel Film Studios creating a ... select from up to two layers of subject matter along with fully customizable backdrop ... Final Cut Pro X. , With ProSlideshow Portrait each user are given ...
(Date:9/21/2017)... ... 21, 2017 , ... Process Capability Indices for Medical Device ... ET, http://www.fdanews.com/processcapabilityindices      , Quality in device manufacturing is ... Quality System Regulation (§820.250), and Devicemakers find themselves staring at a warning letter. ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... ... ... – Monday, September 18 th .The Brain Tumor Foundation (BTF) begins ... the public.Where:  BTF,s Mobile MRI Unit – a ... Washington, D.C.What:BTF brings its nationwide initiative, the Road to Early Detection Sponsor-A-City ...
(Date:9/9/2017)... Lilly and Company (NYSE: LLY ) will ... an investigational, oral, first-in-class molecule for the acute treatment ... placebo in the Phase 3 SPARTAN study. Detailed results ... the International Headache Society (IHC) in Vancouver ... lasmiditan,s potential to reduce pain and provide freedom from ...
(Date:9/7/2017)... MIRAGE, Calif. , Sept. 7, 2017  For nearly two decades, ... service in the Assisted Reproduction Insurance industry. Today, New Life Agency announces ... fertility medications. ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ... ...
Breaking Medicine Technology: